ArticleZhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatology2021
[Progress of therapeutic vaccinations for chronic hepatitis B].
Article in Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed, 1 citations in OpenAlex.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
Abstract
Chronic hepatitis B (CHB) causes approximately 30% cirrhosis and 53% liver cancer in the world, and is still a serious threat to human health. Treatment CHB through therapeutic vaccination has long been a urgent goal of the medical community. In the past two decades, various therapeutic vaccines have been developed and studied in clinical trials, however, few has achieved satisfactory results. Recently, a nanoparticle therapeutic vaccine for CHB, εPA-44, has entered pahse III clinical trial. Results of phase II trial for εPA-44 showed that the vaccine had good safety profile and achieved profound clinical benefits in patients with CHB. Here, we first introduce the rational of therapeutic vaccine for CHB and summarize the progress of clinical trials. Finally, we t review the phase II clinical trial data of εPA-44 and discuss the posssible impact to the development of next generation therapeutic vaccine for CHB.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.